SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma

NCT06323239 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

148

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma

Interventions

RADIATION: SBRT
RADIATION: Low-dose Radiotherapy (LDRT)
DRUG: Toripalimab
DRUG: Gemcitabine
DRUG: Cisplatin
RADIATION: IMRT

Sponsor

Sun Yat-sen University